Peter Stebbins

About Peter Stebbins

Entrepreneurial MedTech leader with a record of scaling businesses, large and small, Fortune 20 and scrappy start-up. Board Chair. Keen ability to swiftly understand a business, identify needs and opportunities, apply analytics, and steer organizations in strategy implementation. Currently applying broad expertise to steer small & mid-size companies and investors - deeply involved in Go to Market, Fund-raising, IP, M&A, KOLs, Branding, and US market entry. Both a Deal Guy and an Operator. End-to-end business acumen. “5-tool player.” Can galvanize cross-functional teams, partner with clinicians and inventors, and win market access. A connector and change agent who gets stuff done. Curated strategic advisory positions indexed toward digital: Augmented Reality (OnPoint), Enterprise SaaS Sales Targeting (AcuityMD), and Cloud-based Prior Authorizations (Voluware). Executive Chair of an Israeli biosurgery company (Nurami). Increasing strength in the Pharma<>Device intersection with Star Trek-like tele-injection program developed in partnership with Advanced Research Program Agency-Health (DARPA for Health). Record of Growing and Evolving Companies through a Variety of Skills: • STRATEGY and VISION Wrote strategy that became roadmap for Ethicon Biosurgery BU (now $1.4B from $70M). Built the first e-business strategy for JJMD across EMEA, 10 divisions and 20+ countries. • BEGINNING-TO-END DEAL MAKING By owning both strategy and L&A, drove synced-up process for M&A, License/Distribution deals, and Early Stage/VC Partnerships - from landscaping to target to deal and integration. • DRIVING COMMERCIAL BUSINESS GROWTH Played key role in growing Mitek from $100M to $650M through product launches, market creation, new market access capabilities, and deals. Led Codman portfolio into high growth Neurovascular (now Cerenovus BU). Revitalized SURGICEL hemostats portfolio as its first Product Director at Ethicon. • SUPPLY CHAIN AS STRATEGIC LEVER Executed a matrix of major programs including automation of suture manufacturing, product launches, and network optimization at Ethicon - reducing headcount by 1800 and saving $70m/year while re-establishing product superiority over US Surgical. Drove $1B+, 14 plant contract manufacturing collaboration. • PORTFOLIO MANAGEMENT - Carve-out DivesituresConsistently overachieved targets by crafting cohesive and compelling storylines. For example, sale of Advanced Sterilization Products for $2.8B (vs. WSJ estimate of $2.0B) and divestiture of Codman Instruments ($170M) without banker.

Experience

1. Strategic Advisor

   AcuityMD

   Jul 2021 — Present

   Enterprise SaaS Targeting Platform for Medical Device Companies

Education

• Harvard Business School Executive Education

  Private Equity and Venture Capital

• Harvard Business School

  MBA

  1991

• Princeton University

  BS Eng, Chemical Engineering

  1985

Skills

• Experienced Change Agent
• Working with Surgeons
• People Development
• Fda
• Analytics
• Growth Strategies
• Business Strategy
• Commercialization
• Portfolio Management
• Competitive Analysis
• Start-Ups
• Cross-Functional Team Leadership
• Global Marketing
• Marketing Strategy
• Key Opinion Leaders
• Neurostimulation
• Mergers & Acquisitions
• Biotechnology
• Strategy
• Neurosurgery
• Working with Venture Capital Based Companies
• Management Board
• Medical Devices
• Divestitures
• Premarket Approval (Pma)
• Product Development
• Market Development
• Orthopedic Biologics
• Regulatory Approval Paths for Devices
• Cross-Functional Problem Solving
• Sports Medicine
• Product Launch
• Medical Device Public Policy
• Neurovascular
• Healthcare Reimbursement
• Med Device Geek
• Market Analysis